Ourania Tatsis

CIK: 0001789815

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)14 (42.4%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)9 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)10 (30.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

VRTX

VERTEX PHARMACEUTICALS INC / MA

Officer

ODTX

Odyssey Therapeutics, Inc.

Director

VERV

Verve Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (33 total)

VRTX
VERTEX PHARMACEUTICALS INC / MA
Jul 21, 2026
Award(A)
Direct
8.3K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jul 2, 2026
Sale(S)
Direct
1.5K shares at avg. $524.99$787K
ODTX
Odyssey Therapeutics, Inc.
May 7, 2026
Award(A)
Stock Option (Right to Buy)
Direct
27.4K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 25, 2026
Sale(S)
Direct
260 shares at avg. $486.35$126K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 24, 2026
Tax Payment(F)
Direct
1.6K shares at avg. $485.11$789K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 18, 2026
Sale(S)
Direct
368 shares at avg. $473.68$174K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Tax Payment(F)
Direct
2.3K shares at avg. $483.75$1.1M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Sale(S)
Direct
609 shares at avg. $489.46$298K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Award(A)
Direct
5.8K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 13, 2026
Sale(S)
Direct
1.5K shares at avg. $499.99$750K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 13, 2026
Tax Payment(F)
Direct
3.8K shares at avg. $487.76$1.9M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 11, 2026
Sale(S)
Direct
466 shares at avg. $460.43$215K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 10, 2026
Tax Payment(F)
Direct
2.1K shares at avg. $468.41$1.0M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jan 22, 2026
Award(A)
Direct
3.9K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jan 22, 2026
Award(A)
Direct
7.9K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jan 7, 2026
Sale(S)
Direct
4.5K shares at avg. $474.99$2.1M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
4.5K shares at avg. $449.99$2.0M
VERV
Verve Therapeutics, Inc.
Jul 25, 2025
Disposition(D)
Stock Option (right to buy)
Direct
42.2K shares-
VERV
Verve Therapeutics, Inc.
Jul 25, 2025
Disposition(D)
Stock Option (right to buy)
Direct
267.5K shares-
VERV
Verve Therapeutics, Inc.
Jun 5, 2025
Award(A)
Stock Option (right to buy)
Direct
42.2K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Mar 10, 2025
Sale(S)
Direct
3.2K shares at avg. $499.99$1.6M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Mar 4, 2025
Sale(S)
Direct
4.1K shares at avg. $485.49$2.0M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 27, 2025
Sale(S)
Direct
530 shares at avg. $475.34$252K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 26, 2025
Tax Payment(F)
Direct
5K shares at avg. $479.61$2.4M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 25, 2025
Sale(S)
Direct
354 shares at avg. $480.95$170K

		Type	Shares	Price		Ownership
Jul 21, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	8,251	-	$0	Direct
Jul 2, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	1,500	$524.99	$787,485	Direct
May 7, 2026	ODTX Odyssey Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	27,393	-	-	Direct
Feb 25, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	260	$486.35	$126,451	Direct
Feb 24, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	1,627	$485.11	$789,274	Direct
Feb 18, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	368	$473.68	$174,314	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	2,294	$483.75	$1,109,723	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	609	$489.46	$298,081	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	5,789	-	$0	Direct
Feb 13, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	1,500	$499.99	$749,985	Direct
Feb 13, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	3,804	$487.76	$1,855,439	Direct
Feb 11, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	466	$460.43	$214,560	Direct
Feb 10, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	2,140	$468.41	$1,002,397	Direct
Jan 22, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	3,883	-	$0	Direct
Jan 22, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	7,866	-	$0	Direct
Jan 7, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	4,500	$474.99	$2,137,455	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	4,500	$449.99	$2,024,955	Direct
Jul 25, 2025	VERV Verve Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	42,200	-	-	Direct
Jul 25, 2025	VERV Verve Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	267,541	-	-	Direct
Jun 5, 2025	VERV Verve Therapeutics, Inc.	Award(A) Stock Option (right to buy)	42,200	-	-	Direct
Mar 10, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	3,242	$499.99	$1,620,968	Direct
Mar 4, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	4,058	$485.49	$1,970,118	Direct
Feb 27, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	530	$475.34	$251,930	Direct
Feb 26, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	4,962	$479.61	$2,379,825	Direct
Feb 25, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	354	$480.95	$170,256	Direct

1-25 of 33 transactions

About Tatsis Ourania

Tatsis Ourania (SEC CIK 0001789815) files insider reports with the SEC as EVP, Chief Reg. & Quality Off. of VERTEX PHARMACEUTICALS INC / MA (VRTX), Director of Odyssey Therapeutics, Inc. (ODTX) and Director of Verve Therapeutics, Inc. (VERV).

Signal8 holds 21 ownership filings by Tatsis Ourania (1 Form 3, 20 Form 4), filed between Feb 6, 2025 and Jul 23, 2026. Those filings report 33 transactions, from Feb 4, 2025 to Jul 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tatsis Ourania's filings is in BOSTON, MA.

Recent filings by Tatsis Ourania

Jul 21, 2026: Grant or award of VRTX shares (Form 4, code A).
Jul 2, 2026: Open-market sale of VRTX shares (Form 4, code S).
May 7, 2026: Grant or award of ODTX derivative securities (Form 4, code A).
Feb 25, 2026: Open-market sale of VRTX shares (Form 4, code S).
Feb 24, 2026: Tax withholding of VRTX shares (Form 4, code F).

Other insiders filing for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Brennan Daniel J., Director
SACHS BRUCE I, Director
Garber Alan M, Director
van Grunsven Jasper, EVP, CP and NPPO
Ambrose Kristen, SVP & Chief Accounting Officer
Sachdev Amit, EVP Chief Patient & Ext Af Off

How to read Form 4 transaction codes